【摘要】 脉络膜新生血管(choroidal neovascularization, CNV)与眼内疾病密切相关,是引起视力严重下降的主要病理因素之一。抑制CNV生长是此类疾病当前临床治疗关键,也是该基础研究领域的核心问题。本文就糖皮质激素在眼内CNV的实验研究和临床治疗方面进行相关综述。
【关键词】 糖皮质激素;脉络膜新生血管
Review of glucocorticoid and diseases with choroidal neovascularization
Jian-Feng Xu, Yu-Sheng Wang
Foundation items: Natural Science Foundation of Shaanxi Province (No.2004C246) and Scientific and Technological innovation Foundation of Xijing Hospital (No.XJCX04M003)
Department of Ophthalmology, Institute of Ophthalmology of Chinese PLA, Xijing Hospital, the Fourth Military Medical University, Xi'an 710032, Shaanxi Province, China.
AbstractChoroidal neovascularization (CNV) is the main pathologic factor of severe visual loss. Currently, the prevention and cure of CNV is the key of clinical therapy and the core of elementary research. This article reviewed about the investigative actuality of glucocorticoid on CNV.
· KEYWORDS: glucocorticoid; choroidal neovascularization
0引言
脉络膜新生血管(CNV)常见于年龄相关性黄斑变性(AMD)、特发性CNV、病理性近视、血管样条纹等眼底病变,是中心视力不可逆损害的病理基础[1]。目前多种治疗方法,如手术、激光及放射治疗等均是在CNV生成后进行对症治疗,并未从病因或病变发展进程中阻断CNV,因而效果均不满意。从理论上来讲,治疗CNV的关键在于针对其发病机制而阻断其发展过程,抗新生血管治疗就基于此。药物治疗是目前最有希望阻断CNV病变发展进程的抗新生血管治疗方法之一。研究表明[2],糖皮质激素(glucocorticoid, GC)可通过改变细胞外基质的降解等多种途径来抑制新生血管形成。本文就GC在抑制眼内CNV中的生物学效应、作用机制及其在基础与临床方面的研究进行较为全面的综述。
[1] [2] [3] [4] [5] [6] 下一页 |